How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early‐Stage Neuronal Alpha‐Synuclein Disease
Tanya Simuni, Christopher S. Coffey, Catherine Kopil, Cora Allen‐Savietta et autres
The Path to Prevention (P2P) platform trial is a multicenter, multi-regimen, proof of concept, phase 2A, randomized clinical trial evaluating the safety and early efficacy of investigational products for the treatment of early-stage Neuronal Alpha-Synuclein disease (NSD) populations. The P2P trial is …
us (code pays fourni par la source)
2 citations
Annals of Neurology